The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
ORNL and three partnering institutions have received $4.2 million over three years to apply artificial intelligence to the advancement of complex systems in which human decision making could be enhanced via technology.
From materials science and earth system modeling to quantum information science and cybersecurity, experts in many fields run simulations and conduct experiments to collect the abundance of data necessary for scientific progress.
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
Each year, approximately 6 billion gallons of fuel are wasted as vehicles wait at stop lights or sit in dense traffic with engines idling, according to US Department of Energy estimates.
As the second-leading cause of death in the United States, cancer is a public health crisis that afflicts nearly one in two people during their lifetime.
A typhoon strikes an island in the Pacific Ocean, downing power lines and cell towers. An earthquake hits a remote mountainous region, destroying structures and leaving no communication infrastructure behind.
ORNL computer scientist Catherine Schuman returned to her alma mater, Harriman High School, to lead Hour of Code activities and talk to students about her job as a researcher.
Students often participate in internships and receive formal training in their chosen career fields during college, but some pursue professional development opportunities even earlier.
Artificial intelligence (AI) techniques have the potential to support medical decision-making, from diagnosing diseases to prescribing treatments. But to prioritize patient safety, researchers and practitioners must first ensure such methods are accurate.